Literature DB >> 33436706

A pre-operative prognostic score for the selection of patients for salvage surgery after recurrent head and neck squamous cell carcinomas.

Valentina Lupato1, Jerry Polesel2, Fabio Biagio La Torre1, Giuseppe Fanetti3, Elisabetta Fratta4, Carlo Gobitti5, Gustavo Baldassarre6, Emanuela Vaccher7, Giovanni Franchin5, Vittorio Giacomarra1.   

Abstract

Salvage surgery in recurrent head and neck squamous cell carcinoma has a poor outcome, both in terms of survival and quality of life. Therefore, the identification of pre-operative prognostic factors to improve the selection of patients who could benefit the most from salvage surgery is clinically relevant. The present study is a single-center retrospective analysis of 164 patients treated with salvage surgery after recurrence of head and neck cancer. Progression free survival and overall survival were calculated through Kaplan-Meier method. Hazard risk (HR) and corresponding confidence intervals (CI) were estimated through Cox proportional hazard model, adjusting for potential confounders. Significant predictors were combined into a prognostic score, attributing one point to each factor. Progression-free survival and overall survival were respectively 50.3% and 56.5% at 2 years, and 36.6% and 44.2% at 5 years. Four pre-operative factors were independently associated with poor prognosis: age > 70 years (HR = 2.18; 95% CI 1.27-3.73), initial stage IV (HR = 2.37; 95% CI 1.18-4.76), disease free interval < 12 months (HR = 1.72; 95% CI 1.01-2.94), and loco-regional recurrence (HR = 2.22; 95% CI 1.22-4.04). No post operative factor was associated with oncologic outcomes. Patients with 3-4 unfavorable factors showed a 5-year overall survival of 0.0% compared to 65.7% in those with 0-1 unfavorable factors (HR = 5.61; 95% CI 2.89-10.92). Despite the low number of patients, 3-4 unfavorable factors were associated to worse prognosis in all sub-sites. In conclusion, age > 70 years, initial stage IV, disease-free interval < 12 months, and loco-regional recurrence are strong independent pre-operative predictors of poor outcome in patients undergoing salvage surgery. Patients with two or more of these factors should be informed about the low success rate after salvage surgery and alternative treatments should be considered.

Entities:  

Mesh:

Year:  2021        PMID: 33436706      PMCID: PMC7804332          DOI: 10.1038/s41598-020-79759-0

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  37 in total

1.  Vascularization in the transition area between free grafted soft tissues and pre-irradiated graft bed tissues following preoperative radiotherapy in the head and neck region.

Authors:  Stefan Schultze-Mosgau; Gerhard G Grabenbauer; Martin Radespiel-Tröger; Joörg Wiltfang; Jutta Ries; Friedrich Wilhelm Neukam; Franz Rödel
Journal:  Head Neck       Date:  2002-01       Impact factor: 3.147

2.  Treatment results and prognostic factors for advanced squamous cell carcinoma of the head and neck treated with salvage surgery after concurrent chemoradiotherapy.

Authors:  Takahide Taguchi; Goshi Nishimura; Masahiro Takahashi; Osamu Shiono; Masanori Komatsu; Daisuke Sano; Ken-Ichiro Yabuki; Yasuhiro Arai; Yukiko Yamashita; Kaoru Yamamoto; Yasunori Sakuma; Nobuhiko Oridate
Journal:  Int J Clin Oncol       Date:  2016-02-23       Impact factor: 3.402

Review 3.  Practical considerations in the re-irradiation of recurrent and second primary head-and-neck cancer: who, why, how, and how much?

Authors:  Allen M Chen; Theodore L Phillips; Nancy Y Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-01       Impact factor: 7.038

4.  Comparison of salvage surgery for recurrent or residual head and neck squamous cell carcinoma.

Authors:  Takashi Maruo; Sadamoto Zenda; Takeshi Shinozaki; Toshifumi Tomioka; Wataru Okano; Minoru Sakuraba; Makoto Tahara; Ryuichi Hayashi
Journal:  Jpn J Clin Oncol       Date:  2020-03-09       Impact factor: 3.019

5.  Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means?

Authors:  W J Goodwin
Journal:  Laryngoscope       Date:  2000-03       Impact factor: 3.325

6.  Salvage surgery in recurrent head and neck squamous cell carcinoma: Oncologic outcome and predictors of disease free survival.

Authors:  Marc Hamoir; Emma Holvoet; Jerôme Ambroise; Benoît Lengelé; Sandra Schmitz
Journal:  Oral Oncol       Date:  2017-01-28       Impact factor: 5.337

7.  Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Authors:  Jan B Vermorken; Ricard Mesia; Fernando Rivera; Eva Remenar; Andrzej Kawecki; Sylvie Rottey; Jozsef Erfan; Dmytro Zabolotnyy; Heinz-Roland Kienzer; Didier Cupissol; Frederic Peyrade; Marco Benasso; Ihor Vynnychenko; Dominique De Raucourt; Carsten Bokemeyer; Armin Schueler; Nadia Amellal; Ricardo Hitt
Journal:  N Engl J Med       Date:  2008-09-11       Impact factor: 91.245

8.  Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.

Authors:  Corey J Langer; Jonathan Harris; Eric M Horwitz; Nicos Nicolaou; Merrill Kies; Walter Curran; Stuart Wong; Kian Ang
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

9.  Selection of Ideal Candidates for Surgical Salvage of Head and Neck Squamous Cell Carcinoma: Effect of the Charlson-Age Comorbidity Index and Oncologic Characteristics on 1-Year Survival and Hospital Course.

Authors:  JeeHong Kim; Seungwon Kim; William G Albergotti; Phillip A Choi; Daniel James Kaplan; Shira Abberbock; Jonas T Johnson; Neil Gildener-Leapman
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2015-12       Impact factor: 6.223

10.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.